In line with this notion, it was found that KRAS mutation was associated with an inflammatory TME and tumor immunogenicity, leading to higher response of patients to anti-PD-1/PD-L1 immunotherapy in NSCLC patients (98). Here, CD274 is linked to neoplasm.